Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis
H De Lavallade, JF Apperley, JS Khorashad… - Journal of Clinical …, 2008 - ascopubs.org
Purpose Imatinib is remarkably effective in treating newly diagnosed patients with chronic
myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come …
myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come …
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses
JE Cortes, HM Kantarjian, SL Goldberg… - Journal of clinical …, 2009 - ascopubs.org
Purpose Long-term clinical outcome data have established imatinib 400 mg/d as standard
front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML) …
front-line treatment for newly diagnosed patients with chronic myeloid leukemia (CML) …
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
BJ Druker, F Guilhot, SG O'Brien… - … England Journal of …, 2006 - Mass Medical Soc
Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …
Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS …
BJ Druker, F Guilhot, S O'Brien… - Journal of Clinical …, 2006 - ascopubs.org
6506 Background: IM was proven to be superior to IFN+ Ara-C for newly diagnosed patients
(pts) with CML-CP (O'Brien et al, NEJM 2003). 1,106 pts were randomized between June …
(pts) with CML-CP (O'Brien et al, NEJM 2003). 1,106 pts were randomized between June …
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia
R Hehlmann, M Lauseker, S Jung-Munkwitz… - Journal of clinical …, 2011 - ascopubs.org
Purpose Treatment of chronic-phase (CP) chronic myeloid leukemia (CML) with imatinib 400
mg/d can be unsatisfactory. Optimization of treatment is warranted. Patients and Methods In …
mg/d can be unsatisfactory. Optimization of treatment is warranted. Patients and Methods In …
The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or …
JA Zonder, P Pemberton, H Brandt, AN Mohamed… - Clinical cancer …, 2003 - AACR
Purpose: Imatinib mesylate is a tyrosine kinase inhibitor with high affinity for the BCR-ABL
fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia …
fusion protein expressed by the hematopoietic cells in chronic myelogenous leukemia …
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib
C Gambacorti-Passerini, L Antolini… - Journal of the …, 2011 - academic.oup.com
Background Imatinib slows development of chronic myeloid leukemia (CML). However,
available information on morbidity and mortality is largely based on sponsored trials …
available information on morbidity and mortality is largely based on sponsored trials …
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid …
JE Cortes, M Baccarani, F Guilhot, BJ Druker… - Journal of Clinical …, 2010 - ascopubs.org
Purpose To evaluate the safety and efficacy of initial treatment with imatinib mesylate 800
mg/d (400 mg twice daily) versus 400 mg/d in patients with newly diagnosed chronic …
mg/d (400 mg twice daily) versus 400 mg/d in patients with newly diagnosed chronic …
Long-term outcomes of imatinib treatment for chronic myeloid leukemia
A Hochhaus, RA Larson, F Guilhot… - … England Journal of …, 2017 - Mass Medical Soc
Background Imatinib, a selective BCR-ABL1 kinase inhibitor, improved the prognosis for
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses …
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase
HM Kantarjian, RA Larson, F Guilhot, SG O'Brien… - Cancer, 2009 - Wiley Online Library
BACKGROUND: Imatinib mesylate given orally at a daily dose of 400 mg is the standard of
care as initial therapy for patients with chronic myeloid leukemia (CML) in chronic phase …
care as initial therapy for patients with chronic myeloid leukemia (CML) in chronic phase …